CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
CRISPR Therapeutics (CRSP) on Saturday announced new results from a Phase 1 trial for CTX310, an in vivo gene editing therapy for patients with high levels of triglycerides and low-density lipoprotein ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results